Stock Track | TG Therapeutics Plunges 5.08% as Profit Margins Shrink and Valuation Concerns Mount

Stock Track11-04

TG Therapeutics (TGTX) experienced a significant 24-hour plunge of 5.08% in pre-market trading, as investors reacted to the company's latest financial report showing a sharp decline in profit margins. The biotech firm's stock price dropped following news of its net profit margin falling to 13.3% from 27.6% in the previous year, raising concerns about the company's premium valuation.

The company's financial performance has come under scrutiny as its Price-to-Earnings ratio of 81.3x significantly exceeds both the biotech peer average of 57.3x and the broader US biotech industry's 17.7x. Despite strong long-term growth potential, with five-year annual earnings growth averaging 48.3% and projected yearly earnings gains of 35.8%, the shrinking profit margins have sparked investor worries about the sustainability of TG Therapeutics' high valuation multiples.

Looking ahead, analysts project that TG Therapeutics' net profit margins could potentially triple to 38.1% by 2028, driven by improved commercial execution and higher patient uptake. However, the wide range of analyst forecasts, with earnings estimates for 2028 varying from $276.6 million to $525 million, underscores the uncertainty surrounding the company's future profitability. As investors reassess the risk-reward profile of TG Therapeutics, the stock's premium valuation may continue to face pressure in the near term.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1196556650?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 16:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196556650","market":"nz","top_or_hot":-1,"title":"Stock Track | TG Therapeutics Plunges 5.08% as Profit Margins Shrink and Valuation Concerns Mount","media":"Stock Track","content":"<p>TG Therapeutics (TGTX) experienced a significant 24-hour plunge of 5.08% in pre-market trading, as investors reacted to the company's latest financial report showing a sharp decline in profit margins. The biotech firm's stock price dropped following news of its net profit margin falling to 13.3% from 27.6% in the previous year, raising concerns about the company's premium valuation.</p>\n\n<p>The company's financial performance has come under scrutiny as its Price-to-Earnings ratio of 81.3x significantly exceeds both the biotech peer average of 57.3x and the broader US biotech industry's 17.7x. Despite strong long-term growth potential, with five-year annual earnings growth averaging 48.3% and projected yearly earnings gains of 35.8%, the shrinking profit margins have sparked investor worries about the sustainability of TG Therapeutics' high valuation multiples.</p>\n\n<p>Looking ahead, analysts project that TG Therapeutics' net profit margins could potentially triple to 38.1% by 2028, driven by improved commercial execution and higher patient uptake. However, the wide range of analyst forecasts, with earnings estimates for 2028 varying from $276.6 million to $525 million, underscores the uncertainty surrounding the company's future profitability. As investors reassess the risk-reward profile of TG Therapeutics, the stock's premium valuation may continue to face pressure in the near term.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | TG Therapeutics Plunges 5.08% as Profit Margins Shrink and Valuation Concerns Mount</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | TG Therapeutics Plunges 5.08% as Profit Margins Shrink and Valuation Concerns Mount\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-04 16:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TG Therapeutics (TGTX) experienced a significant 24-hour plunge of 5.08% in pre-market trading, as investors reacted to the company's latest financial report showing a sharp decline in profit margins. The biotech firm's stock price dropped following news of its net profit margin falling to 13.3% from 27.6% in the previous year, raising concerns about the company's premium valuation.</p>\n\n<p>The company's financial performance has come under scrutiny as its Price-to-Earnings ratio of 81.3x significantly exceeds both the biotech peer average of 57.3x and the broader US biotech industry's 17.7x. Despite strong long-term growth potential, with five-year annual earnings growth averaging 48.3% and projected yearly earnings gains of 35.8%, the shrinking profit margins have sparked investor worries about the sustainability of TG Therapeutics' high valuation multiples.</p>\n\n<p>Looking ahead, analysts project that TG Therapeutics' net profit margins could potentially triple to 38.1% by 2028, driven by improved commercial execution and higher patient uptake. However, the wide range of analyst forecasts, with earnings estimates for 2028 varying from $276.6 million to $525 million, underscores the uncertainty surrounding the company's future profitability. As investors reassess the risk-reward profile of TG Therapeutics, the stock's premium valuation may continue to face pressure in the near term.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TGTX","symbol_name":"TG Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1196556650","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196556650","pubTimestamp":1762245755,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"TG Therapeutics (TGTX) experienced a significant 24-hour plunge of 5.08% in pre-market trading, as investors reacted to the company's latest financial report showing a sharp decline in profit...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TGTX":"TG Therapeutics Inc."},"translate_title":"个股追踪|TG Therapeutics暴跌5.08%利润率萎缩估值担忧升温","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TGTX":1},"content_text":"TG Therapeutics (TGTX) experienced a significant 24-hour plunge of 5.08% in pre-market trading, as investors reacted to the company's latest financial report showing a sharp decline in profit margins. The biotech firm's stock price dropped following news of its net profit margin falling to 13.3% from 27.6% in the previous year, raising concerns about the company's premium valuation.\nThe company's financial performance has come under scrutiny as its Price-to-Earnings ratio of 81.3x significantly exceeds both the biotech peer average of 57.3x and the broader US biotech industry's 17.7x. Despite strong long-term growth potential, with five-year annual earnings growth averaging 48.3% and projected yearly earnings gains of 35.8%, the shrinking profit margins have sparked investor worries about the sustainability of TG Therapeutics' high valuation multiples.\nLooking ahead, analysts project that TG Therapeutics' net profit margins could potentially triple to 38.1% by 2028, driven by improved commercial execution and higher patient uptake. However, the wide range of analyst forecasts, with earnings estimates for 2028 varying from $276.6 million to $525 million, underscores the uncertainty surrounding the company's future profitability. As investors reassess the risk-reward profile of TG Therapeutics, the stock's premium valuation may continue to face pressure in the near term.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1196556650","isCrawlerRequest":true}